These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 11755273)

  • 1. The impact of low levels of amorphous material (<5%) on the blending characteristics of a direct compression formulation.
    Mackin L; Sartnurak S; Thomas I; Moore S
    Int J Pharm; 2002 Jan; 231(2):213-26. PubMed ID: 11755273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of powder blend uniformity: Comparison of real-time NIR blend monitoring with stratified sampling in combination with HPLC and at-line NIR Chemical Imaging.
    Bakri B; Weimer M; Hauck G; Reich G
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):78-89. PubMed ID: 26455421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of process parameters on content uniformity of a low dose active pharmaceutical ingredient in a tablet formulation according to GMP.
    Muselík J; Franc A; Doležel P; Goněc R; Krondlová A; Lukášová I
    Acta Pharm; 2014 Sep; 64(3):355-67. PubMed ID: 25296681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation into the effects of excipient particle size, blending techniques and processing parameters on the homogeneity and content uniformity of a blend containing low-dose model drug.
    Alyami H; Dahmash E; Bowen J; Mohammed AR
    PLoS One; 2017; 12(6):e0178772. PubMed ID: 28609454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mixing of low-dose cohesive drug and overcoming of pre-blending step using a new gentle-wing high-shear mixer granulator.
    Alsulays BB; Fayed MH; Alalaiwe A; Alshahrani SM; Alshetaili AS; Alshehri SM; Alanazi FK
    Drug Dev Ind Pharm; 2018 Sep; 44(9):1520-1527. PubMed ID: 29718720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a continuous direct compression platform for low-dose drug products.
    Van Snick B; Holman J; Vanhoorne V; Kumar A; De Beer T; Remon JP; Vervaet C
    Int J Pharm; 2017 Aug; 529(1-2):329-346. PubMed ID: 28684361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of blend uniformity and content uniformity based on 2003 stratified sampling guidance and 1999 blend uniformity analysis guidance: product A.
    Howard-Sparks M; Gawlikowski A;
    PDA J Pharm Sci Technol; 2004; 58(4):222-30. PubMed ID: 15368992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A quality-by-design study for an immediate-release tablet platform: examining the relative impact of active pharmaceutical ingredient properties, processing methods, and excipient variability on drug product quality attributes.
    Kushner J; Langdon BA; Hicks I; Song D; Li F; Kathiria L; Kane A; Ranade G; Agarwal K
    J Pharm Sci; 2014 Feb; 103(2):527-38. PubMed ID: 24375069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of small amorphous amounts in hydrophilic and hydrophobic APIs on storage stability of dry powder inhalation products.
    Müller T; Krehl R; Schiewe J; Weiler C; Steckel H
    Eur J Pharm Biopharm; 2015 May; 92():130-8. PubMed ID: 25769680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commercial scale validation of a process scale-up model for lubricant blending of pharmaceutical powders.
    Kushner J; Schlack H
    Int J Pharm; 2014 Nov; 475(1-2):147-55. PubMed ID: 25152166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of a blend-sampling technique to assess the uniformity of a powder mixture.
    Garcia TP; Wilkinson SJ; Scott JF
    Drug Dev Ind Pharm; 2001 Apr; 27(4):297-307. PubMed ID: 11411897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blend uniformity end-point determination using near-infrared spectroscopy and multivariate calibration.
    Sulub Y; Konigsberger M; Cheney J
    J Pharm Biomed Anal; 2011 Jun; 55(3):429-34. PubMed ID: 21398064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
    Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP
    Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous direct compression as manufacturing platform for sustained release tablets.
    Van Snick B; Holman J; Cunningham C; Kumar A; Vercruysse J; De Beer T; Remon JP; Vervaet C
    Int J Pharm; 2017 Mar; 519(1-2):390-407. PubMed ID: 28069390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Manufacture and performance evaluation of a stable amorphous complex of an acidic drug molecule and Neusilin.
    Maclean J; Medina C; Daurio D; Alvarez-Nunez F; Jona J; Munson E; Nagapudi K
    J Pharm Sci; 2011 Aug; 100(8):3332-3344. PubMed ID: 21520086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physical and lubrication properties of magnesium stearate.
    Leinonen UI; Jalonen HU; Vihervaara PA; Laine ES
    J Pharm Sci; 1992 Dec; 81(12):1194-8. PubMed ID: 1491339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of low levels (<10%) of amorphous content in micronised active batches using dynamic vapour sorption and isothermal microcalorimetry.
    Mackin L; Zanon R; Park JM; Foster K; Opalenik H; Demonte M
    Int J Pharm; 2002 Jan; 231(2):227-36. PubMed ID: 11755274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Applications of NIR in early stage formulation development. Part I. Semi-quantitative blend uniformity and content uniformity analyses by reflectance NIR without calibration models.
    Li W; Bashai-Woldu A; Ballard J; Johnson M; Agresta M; Rasmussen H; Hu S; Cunningham J; Winstead D
    Int J Pharm; 2007 Aug; 340(1-2):97-103. PubMed ID: 17467204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets.
    Eddington ND; Ashraf M; Augsburger LL; Leslie JL; Fossler MJ; Lesko LJ; Shah VP; Rekhi GS
    Pharm Dev Technol; 1998 Nov; 3(4):535-47. PubMed ID: 9834957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robustness of a continuous direct compression line against disturbances in feeding.
    Karttunen AP; Poms J; Sacher S; Sparén A; Ruiz Samblás C; Fransson M; Martin De Juan L; Remmelgas J; Wikström H; Hsiao WK; Folestad S; Korhonen O; Abrahmsén-Alami S; Tajarobi P
    Int J Pharm; 2020 Jan; 574():118882. PubMed ID: 31786355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.